ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
November 09 2020 - 6:30AM
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage
oncology company focused on developing treatments that address
mechanisms of therapeutic resistance, today announced that Jacob
Chacko, M.D., chief executive officer, will participate in the
following investor conferences in November:
- Jefferies Virtual
London Healthcare Conference –
Participating in a virtual fireside chat on November 18, 2020 at
5:00 p.m. GMT/9:00 a.m. PT; and
- SVB
Leerink Oncology 1x1 Day –
Hosting virtual investor meetings on November 19, 2020
A live webcast of the fireside chat will be
available through the investor section of the company’s website at
www.oricpharma.com. A replay of the webcast will be available
for 90 days following the events.
About ORIC Pharmaceuticals,
Inc.
ORIC Pharmaceuticals is a clinical stage
biopharmaceutical company dedicated to improving patients’ lives by
Overcoming Resistance In Cancer. ORIC’s lead product
candidate, ORIC-101, is a potent and selective small molecule
antagonist of the glucocorticoid receptor, which has been linked to
resistance to multiple classes of cancer therapeutics across a
variety of solid tumors. ORIC-101 is currently in two separate
Phase 1b trials of ORIC-101 in combination with (1) Xtandi
(enzalutamide) in metastatic prostate cancer and (2) Abraxane
(nab-paclitaxel) in advanced or metastatic solid tumors.
ORIC’s other product candidates include (1) ORIC-533, an orally
bioavailable small molecule inhibitor of CD73, a key node in the
adenosine pathway believed to play a central role in resistance to
chemotherapy- and immunotherapy-based treatment regimens, (2)
ORIC-944, an allosteric inhibitor of the polycomb repressive
complex 2 (PRC2) via the EED subunit, being developed for prostate
cancer, and (3) ORIC-114, a brain penetrant inhibitor designed to
selectively target EGFR and HER2 with high potency against exon 20
insertion mutations, being developed across multiple genetically
defined cancers. Beyond these four product candidates, ORIC is also
developing multiple precision medicines targeting other hallmark
cancer resistance mechanisms. ORIC has offices in South San
Francisco and San Diego, California. For more information, please
go to www.oricpharma.com.
Contact:Dominic Piscitelli,
Chief Financial Officer
dominic.piscitelli@oricpharma.cominfo@oricpharma.com
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oric Pharmaceuticals (NASDAQ:ORIC)
Historical Stock Chart
From Jul 2023 to Jul 2024